Aktis Oncology, Inc.
NASDAQAktis Oncology reaches its May 22 earnings date with the short-seller dynamic that had been easing now quietly reversing. The shift is modest but directionally clear. Short interest has climbed roughly 9% over the past month to around 2.45 million shares — a reversal from the deceleration noted ahead of the May 15 print. The ORTEX short score holds at 70.4, essentially unchanged…
Snapshot as of 22 May 2026
Aktis Oncology reaches its May 22 earnings date with the short-seller dynamic that had been easing now quietly reversing. The shift is modest but directionally clear. Short interest has climbed roughly 9% over the past…
Aktis Oncology heads into its May 15 results with a notable split: fresh institutional conviction sits alongside a short-score that remains elevated even as shorts trim positions. The lending market tells a more…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AKTS — free to start on ORTEX.
Sign up for free →Open AKTS on ORTEX